[Efficacy and tolerability of a cardioselective beta-blocking drug (atenolol) in the treatment of essential hypertension. A double blind study (author's transl)]. 1978

F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli

The antihypertensive effect of atenolol, a new beta 1 receptor blocking agent, was studied in a double blind non cross-over trial in 40 patients (pts) affected by mild to moderately severe essential hypertension with normal plasma renin activity. After a run-in period (15 days) of placebo treatment pts were assigned to two groups. The first (group A) continued placebo treatment for 30 days, the second (Group B) were given atenolol (ICI 66082) 100 mg daily for 30 days also. Atenolol significantly reduced systolic and diastolic blood pressure in recumbent and standing position and heart rate at rest. No significantly changes of the same parameters were observed in group A. Body weight and plasma renin activity was unchanged in both groups. Atenolol treatment never was discharged in order to side effects. These results seem to suggest that atenolol can be an useful drug in the treatment of systemic blood hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
May 1980, Chest,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
January 1986, Journal of cardiovascular pharmacology,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
October 1980, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
January 1979, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
April 1971, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
January 1989, Drugs under experimental and clinical research,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
June 1981, Zhonghua xin xue guan bing za zhi,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
January 1989, Indian heart journal,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
October 1990, Journal of human hypertension,
F Rengo, and B Trimarco, and M Petretta, and N Ferrara, and D Bonaduce, and M Chiariello, and M Condorelli
June 1975, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!